Literature DB >> 19013641

Preclinical and clinical experience with dasatinib in Philadelphia chromosome-negative leukemias and myeloid disorders.

Srdan Verstovsek1.   

Abstract

Recent advances in the molecular characterization of Philadelphia chromosome-negative (Ph-) leukemias and related myeloid disorders have provided a clear rationale for investigating novel targeted therapies. Dasatinib is a tyrosine kinase inhibitor with activity against BCR-ABL, platelet-derived growth factor receptors (PDGFRs), c- KIT, fibroblast growth factor receptors (FGFRs), SRC family kinases (SFKs), and EPHA receptors, all of which have been implicated in the pathogenesis of Ph- leukemias and myeloid disorders. This review presents emerging data on the preclinical and clinical activity of dasatinib in these diseases, which suggest that larger clinical studies are warranted.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19013641      PMCID： PMC4428150          DOI： 10.1016/j.leukres.2008.10.001

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  69 in total

1.  Src family kinases promote AML cell survival through activation of signal transducers and activators of transcription (STAT).

Authors:  Yukiyasu Ozawa; Ann H Williams; Myka L Estes; Norimasa Matsushita; Frank Boschelli; Richard Jove; Alan F List
Journal:  Leuk Res       Date:  2008-01-07       Impact factor: 3.156

2.  Molecular characterization of acute myeloid leukemia.

Authors:  Konstanze Döhner; Hartmut Döhner
Journal:  Haematologica       Date:  2008-07       Impact factor: 9.941

3.  Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study.

Authors:  Peter Paschka; Guido Marcucci; Amy S Ruppert; Krzysztof Mrózek; Hankui Chen; Rick A Kittles; Tamara Vukosavljevic; Danilo Perrotti; James W Vardiman; Andrew J Carroll; Jonathan E Kolitz; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2006-08-20       Impact factor: 44.544

4.  The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations.

Authors:  Yongsheng Ma; Shan Zeng; Dean D Metcalfe; Cem Akin; Sasa Dimitrijevic; Joseph H Butterfield; Gerald McMahon; B Jack Longley
Journal:  Blood       Date:  2002-03-01       Impact factor: 22.113

5.  JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia.

Authors:  Jaroslav Jelinek; Yasuhiro Oki; Vazganush Gharibyan; Carlos Bueso-Ramos; Josef T Prchal; Srdan Verstovsek; Miloslav Beran; Elihu Estey; Hagop M Kantarjian; Jean-Pierre J Issa
Journal:  Blood       Date:  2005-07-21       Impact factor: 22.113

6.  Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha.

Authors:  Christian Baumgartner; Karoline V Gleixner; Barbara Peter; Veronika Ferenc; Alexander Gruze; Lily L Remsing Rix; Keiryn L Bennett; Puchit Samorapoompichit; Francis Y Lee; Winfried F Pickl; Harald Esterbauer; Christian Sillaber; Giulio Superti-Furga; Peter Valent
Journal:  Exp Hematol       Date:  2008-07-10       Impact factor: 3.084

7.  The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study.

Authors:  Michele Baccarani; Daniela Cilloni; Michela Rondoni; Emanuela Ottaviani; Francesca Messa; Serena Merante; Mario Tiribelli; Francesco Buccisano; Nicoletta Testoni; Enrico Gottardi; Antonio de Vivo; Emilia Giugliano; Ilaria Iacobucci; Stefania Paolini; Simona Soverini; Gianantonio Rosti; Francesca Rancati; Cinzia Astolfi; Fabrizio Pane; Giuseppe Saglio; Giovanni Martinelli
Journal:  Haematologica       Date:  2007-08-01       Impact factor: 9.941

8.  The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leukemias (EGIL).

Authors:  M C Bene; M Bernier; R O Casasnovas; G Castoldi; W Knapp; F Lanza; W D Ludwig; E Matutes; A Orfao; C Sperling; M B van't Veer
Journal:  Blood       Date:  1998-07-15       Impact factor: 22.113

9.  Imatinib effect on growth and signal transduction in polycythemia vera.

Authors:  Amos Gaikwad; Srdan Verstovsek; Donghoon Yoon; Ko-Tung Chang; Taghi Manshouri; Roberto Nussenzveig; Jorge Cortes; William Vainchenker; Josef T Prchal
Journal:  Exp Hematol       Date:  2007-06       Impact factor: 3.084

10.  Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.

Authors:  Jane F Apperley; Martine Gardembas; Junia V Melo; Robin Russell-Jones; Barbara J Bain; E Joanna Baxter; Andrew Chase; Judith M Chessells; Marie Colombat; Claire E Dearden; Sasa Dimitrijevic; François-X Mahon; David Marin; Zariana Nikolova; Eduardo Olavarria; Sandra Silberman; Beate Schultheis; Nicholas C P Cross; John M Goldman
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245
View more
  2 in total

1.  Evidence for the persistence of an active endogenous retrovirus (ERVE) in humans.

Authors:  Horacio Naveira; Xabier Bello; José Luis Abal-Fabeiro; Xulio Maside
Journal:  Genetica       Date:  2014-09-06       Impact factor: 1.082

Review 2.  Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities.

Authors:  Maher Chaar; Jeff Kamta; Sihem Ait-Oudhia
Journal:  Onco Targets Ther       Date:  2018-09-25       Impact factor: 4.147
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.